Why Does Pre-Blend Particle Size Control Content Uniformity in Neostigmine Bromide Tablets?

Direct compression of veterinary neostigmine bromide tablets confines the active pharmaceutical ingredient to 5–15 mg per unit in core masses of 120–250 mg, so the drug load is 2–12.5 % w/w or lower in fixed-dose combinations. The principal process failure is not chemical degradation but segregation during transfer from blender to rotary press. Neostigmine bromide is a hygroscopic quaternary ammonium salt with a plate-like crystal habit in many commercial lots; unmilled material with D₉₀ above 150 µm segregates against spray-dried lactose monohydrate and microcrystalline cellulose in a V-shell or bin blender. When the bulk-density mismatch exceeds 0.25 g/mL, assay values in samples drawn from the press hopper after 15 min of operation can drift by more than 10 % relative to target, driving the acceptance value above 15 under USP <905> and Ph. Eur. 2.9.40. To mitigate this, the API is delumped through a 500 µm stainless-steel screen, then combined with a 1:5 portion of pre-screened filler by geometric dilution. The pre-blend is discharged through a 20 L bin fitted with an intensifier bar running at 600 rpm for 60 s before addition of the remaining excipients. Magnesium stearate is added at 0.5 % w/w only in the final 3 min of blending at 24–30 rpm; the quaternary ammonium surface of neostigmine bromide retains a positive charge across the solid-state mixing environment, and extended lubrication reduces tablet hardness by 20–30 % under the same compression force without changing assay.

After compression, tablet hardness is controlled at 50–80 N for 10.0 mm round flat-faced beveled tooling; friability remains below 1.0 % w/w per USP <1216> / Ph. Eur. 2.9.7. Disintegration in water at 37 °C should complete within 15 min under USP <701> / Ph. Eur. 2.9.1, not because the API has poor aqueous solubility but because the compacted microcrystalline cellulose network can lose wicking if moisture exceeds 3 % w/w at compression. Dissolution testing in 900 mL water at 50 rpm using USP <711> apparatus II typically shows release of more than 80 % of label claim at 30 min when hardness and disintegration are within the stated ranges; published data for fixed-dose veterinary combinations with coated cores are limited per formulation. Final packaging in aluminium/PVC cold-form blisters with desiccant is used where the API is exposed to RH >60 % during storage; bulk tablet containers are not recommended without desiccant in tropical climates.

Injectable Neostigmine Methylsulfate pH Drift and Terminal Sterilisation Limits

Aqueous injectable solutions are prepared from neostigmine methylsulfate rather than the bromide salt because methylsulfate provides a pH-appropriate counterion and avoids the additional tonicity contribution from bromide. The vehicle is Water for Injection sparged with nitrogen to a dissolved oxygen level below 1 mg/L; the solution is buffered to pH 4.5–6.0 using citrate or acetate. Above pH 7.0, base-catalysed hydrolysis of the dimethylcarbamate linkage accelerates, and terminal steam sterilisation at 121 °C for 15 min can produce 3-(dimethylamino)phenol and other related substances that exceed monograph thresholds. The API is charged through a 0.22 µm cartridge filter into a stainless-steel formulation vessel with a bottom-mounted magnetic stirrer at 200–300 rpm; heating during filtration is avoided because the quaternary ammonium head group can increase solution viscosity at high local concentration. After filling into 10 mL or 20 mL Type I glass ampoules or vials, headspace oxygen is reduced to below 2 % v/v before sealing. Terminal sterilisation is run at 121 °C for 15 min with an F₀ value not less than 12 min as required by Ph. Eur. 5.1.1 and current Good Manufacturing Practice; post-sterilisation pH is verified because acetate buffers can shift downward by 0.2–0.5 units during heating.

Particulate matter is evaluated by light obscuration using Ph. Eur. 2.9.19 and USP <788>; visible and subvisible counts are controlled to the limits for small-volume parenterals. Fill volume is checked by Ph. Eur. 2.9.17 / USP <697>; for ampoules, overfill of 0.3–0.5 mL is common to permit withdrawal of the labelled volume. Neostigmine methylsulfate solutions for multi-dose vials require preservative efficacy testing under Ph. Eur. 5.1.3 / USP <51>, but benzalkonium chloride can interact with the quaternary ammonium API and should not be used without recovery studies. Rubber closures containing sulfur-cured elastomers may sorb the API over storage; Type I glass ampoules or fluoropolymer-coated stoppers are preferred. Storage above 25 °C or freeze-thaw cycling can cause pH drift beyond 6.0 and should be avoided unless stability data support broader conditions.

Hard gelatin capsule filling with neostigmine bromide is governed by water activity rather than particle size alone because the API is hygroscopic; the capsule shell becomes brittle when equilibrium relative humidity falls below 40 % and tacky above 60 %. A typical blend is prepared from 5–15 mg API, lactose monohydrate, pregelatinised starch, and 0.25–0.5 % w/w magnesium stearate, pre-blended in a low-shear mixer at 25–30 rpm for 10 min. Final blend moisture is held at 2–3 % w/w loss on drying by Ph. Eur. 2.2.32 / USP <731>. Filling on a dosing-disc or tamping-pin machine for size 1 or 2 capsules should maintain fill weight variability within ±3 % of the mean; variability above ±5 % generates acceptance value failures under USP <905> before dissolution becomes limiting. The API is filled as a non-compacted powder, so dissolution in 900 mL water at 37 °C and 50 rpm is typically rapid once the shell dissolves, but cross-linking of gelatin by aldehyde impurities in lactose or by storage at high temperature and humidity can delay disintegration beyond 15 min. Packaging in PVC/PVDC blisters with a desiccant pouch is used for climate zones III and IVb because the API can increase water activity of the fill and cause shell deformation at room temperature.

The main incompatibility in capsules is not the shell but alkaline fillers such as sodium bicarbonate or carbonate-based buffers, which raise local pH and accelerate dimethylcarbamate hydrolysis. If a fixed-dose combination requires an antacid, a pH-modifying layer or acidified granule is required. Processors typically quarantine filled capsules in an environment of 45–50 % RH for 8–12 h before packaging to allow shell moisture to equilibrate; immediate transfer from a dry filling booth to an uncontrolled warehouse can create stress cracks at the cap shoulder.

If Neostigmine Bromide Is Intended for Oral Powders, Granules, or Feed Premix, Two-Stage Dilution Determines Homogeneity

Oral powders and granules for dilution into drinking water or feed place the API at 0.1–2.0 % w/w in the final product, so a two-stage mixing sequence is necessary to avoid dead spots in the carrier. The first stage consists of triturating neostigmine bromide with an equal mass of lactose monohydrate or dextrose through a 500 µm screen; the second stage dilutes this pre-mix into the remaining carrier in a ribbon blender or paddle mixer run at 60–70 % bulk fill. Samples are drawn from 10 positions in the blender and assayed by HPLC; relative standard deviation above 5 % indicates insufficient dispersion and requires extended mixing in 5-min increments. For granules, top-spray fluid-bed granulation is performed with a 5 % w/w povidone K30 binder solution at an inlet air temperature of 45–55 °C, product temperature of 30–35 °C, and spray rate of 10–20 g/min for a 10 kg batch. The granulation is dried to loss on drying below 2.0 % w/w, then milled through a 1000 µm screen. The resulting granules should have a bulk density of 0.45–0.65 g/mL and a Carr index below 20 % to avoid bridging in the filling line. Published data for neostigmine bromide granulation at commercial scale beyond 50 kg are limited; process limits should be re-qualified because the quaternary ammonium compound can adhere to stainless steel contact surfaces.

Stability in drinking water is an additional constraint. Aqueous dilutions for administration should be prepared on the day of use where possible; neostigmine bromide is chemically stable for 24 h at pH 4.0–6.0 but degrades more rapidly in alkaline or biologically active water. Free chlorine above 0.5 mg/L in the dilution water can oxidise the quaternary ammonium compound and reduce potency before administration; sodium thiosulfate is not added unless compatibility is confirmed. In hard water with total hardness above 150 mg/L CaCO₃, alkalinity can raise pH of unbuffered solutions above 7.5 and should be monitored.

Type A medicated feed premixes containing neostigmine bromide are not simple dilutions into ground corn; carrier particle geometry and oil content determine whether the quaternary ammonium active remains uniformly distributed during pneumatic conveying and auger metering. For feed mills, a carrier of ground rice hulls or limestone with a particle size between 500 µm and 1000 µm is preferred over untreated corn cobs because the irregular surface reduces percolation of the fine API through the carrier. The API is added as a 5–10 % w/w intermediate premix, then diluted to the final Type A concentration in a double-ribbon mixer with a batch cycle of 10–15 min at 30 % fill volume. Medicated feed production is conducted under 21 CFR 225 current Good Manufacturing Practice for medicated feeds, and the final Type A article must carry a withdrawal statement where the target species is food-producing. Sampling is performed at the mixer outlet using 10 spaced increments; relative standard deviation should remain below 5 % for the active fraction. In feed, neostigmine bromide may be susceptible to degradation in the presence of mineral supplements containing high moisture or transition metals; calcium carbonate at levels above 20 % w/w of the premix can raise local pH and reduce recovery during stability testing.

Premixes intended for administration through drinking water should not be confused with feed premixes. Water-dispersible granules require a surfactant system to avoid foaming and incomplete wetting; polysorbate 80 at 0.1–0.3 % w/w of the granule mass is sometimes used, but compatibility with the quaternary ammonium API should be verified by assay and osmolality where applicable. Final use dilution equipment such as proportioners may deliver 0.1–10 mg/L active in drinking water depending on the veterinary product authorisation; in-line calibration should be checked with a conductivity meter or dye tracer because the low concentration makes visual confirmation unreliable.

Oral Neostigmine Solutions Are Compounded Under Acidic pH to Preserve Carbamate Stability

Aqueous oral solutions of neostigmine bromide are compounded at pH 4.0–5.5, because the carbamate ester is most stable under mildly acidic conditions and the acid milieu suppresses microbial growth in sugar-free formulations. The vehicle is purified water adjusted with citric acid and sodium citrate; sorbitol or glycerin may be included at 10–20 % w/w to reduce bitterness and increase viscosity for oral syringe delivery. The API is dissolved in a stainless-steel vessel using a high-shear mixer at 300–600 rpm; the powder is added through a 250 µm in-line mesh to prevent aggregation of the quaternary ammonium salt. The solution is then polished through a 0.45 µm filter and transferred to amber PET or Type III glass bottles; light protection is required because exposure to UV light can generate 3-(dimethylamino)phenol and colour shifts. Preservative efficacy must comply with Ph. Eur. 5.1.3 / USP <51>. Methyl parahydroxybenzoate at 0.08–0.15 % w/w is commonly evaluated; benzalkonium chloride is not preferred unless recovery studies exclude ion-pair formation with the API. Sorption to the closure or container is evaluated by storing inverted bottles at 25 °C/60 % RH and 40 °C/75 % RH for at least 12 weeks; neostigmine bromide can show loss at the liquid–plastic interface in polyethylene terephthalate bottles if the polymer contains high levels of anionic additives.

Viscosity and pH remain the two primary finished-product control points. The pH is measured by Ph. Eur. 2.2.3 / USP <791> and maintained within ±0.2 pH units of the release value; a shift above 6.0 triggers a related-substances investigation by HPLC. Viscosity is measured with a rotational viscometer at 20 °C; the target is typically 10–50 mPa·s for oral syringes, but the specification depends on the closure and dosing device. Microbial enumeration tests are performed by Ph. Eur. 2.6.12 / USP <61>; total aerobic microbial count and total yeast and mould count are set according to the finished product monograph. No terminal sterilisation is applied to oral solutions; therefore, environmental bioburden in the compounding suite is maintained at Grade D or better with continuous monitoring of airborne viable counts.